Healthcare Industry News:  ELIQUIS 

Biopharmaceuticals Generics FDA

 News Release - August 5, 2021

Breckenridge Announces Final Approval of its ANDA for Apixaban Tablets (generic for Eliquis(R))

BERLIN, Conn., Aug. 5, 2021 -- (Healthcare Sales & Marketing Network) -- Breckenridge Pharmaceutical, Inc. announces today that the U.S. Food and Drug Administration has granted final approval of its Abbreviated New Drug Application for Apixaban Tablets (generic for ELIQUIS). This product was developed by Towa Pharmaceutical Europe, S.L. in its manufacturing facility located in Martorelles, Spain. According to industry sales data, ELIQUIS generated annual sales of $14 billion during the twelve months ending May 2021. Breckenridge has been granted a license under confidential terms permitting Breckenridge to launch generic Apixaban Tablets under its Abbreviated New Drug Application at a later date.

About Breckenridge

Breckenridge Pharmaceutical, Inc., a subsidiary of Towa Pharmaceutical (Osaka, Japan), partners with manufacturers nationwide and around the world to bring quality, cost-effective generic pharmaceuticals to U.S. patients. With our dedication to customer service, on-time delivery, reliable supply and quality manufacturing, we improve the health and quality of life of the patients we and our customers serve. www.bpirx.com


Source: Breckenridge Pharmaceutical

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.